Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic ...

Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs as ...

The Oxalosis and Hyperoxaluria Foundation (OHF) has accepted UCSF Health into its OHF Care Center Network recognizing the health system’s dedication to providing high-quality medical care, resources, ...

Brandon Kistler, PhD, RD, took a kidney disease dietetic internship in college that changed the course of his career. He noticed a gap between traditional nutrition advice for patients with kidney ...

Chronic kidney disease (CKD) is typically associated with severe fibrosis, the exact pathogenesis of which remains unclear.

Total adverse events of heart failure or all-cause mortality were reduced with empagliflozin, regardless of kidney function.

A team studied the differences between monogenic and nonmonogenic lupus nephritis and the predictors of end-stage kidney disease. Monogenic lupus nephritis is distinct from non-monogenic disease with ...

FDA issues a complete response letter for oxylanthanum carbonate, a treatment for hyperphosphatemia in patients with chronic ...

Proton pump inhibitor use is implicated in decline in kidney graft function after transplantation. Extended proton pump inhibitor (PPI) use is associated with decline in graft function in kidney ...

Chronic kidney disease articles from across Nature Portfolio Chronic kidney disease (CKD) is defined as a progressive loss of renal function that lasts for more than 3 months, and is classified ...

In 2024, a plethora of novel therapeutic strategies for kidney disease progressed to clinical trials, including an RNA interference therapeutic, a glucagon-like peptide 1 receptor agonist, a ...